AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price reduced by research analysts at JPMorgan Chase & Co. from $66 ...

On Wednesday, Truist Securities adjusted its outlook on shares of AnaptysBio (NASDAQ:ANAB), reducing the stock's price target from $30.00 to $20.00, while maintaining a Hold rating on the shares.

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data On Wednesday, AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the ...

AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to analysts’ expectations of $7 ...

AnaptysBio (ANAB – Research Report) received a Hold rating and price target from BTIG analyst Julian Harrison today. The company’s shares ...

Guggenheim lowered the firm’s price target on AnaptysBio (ANAB) to $36 from $90 and keeps a Buy rating on the shares following the announcement ...

AnaptysBio ANAB has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings ...

Shares of AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company, plunged 32.8% on Dec. 11 after it announced that the phase IIb study of pipeline candidate, ANB032, a BTLA agonist ...

On Wednesday, Truist Securities adjusted its outlook on shares of AnaptysBio (NASDAQ:ANAB), reducing the stock's price target from $30.00 to $20.00, while maintaining a Hold rating on the shares. The ...

I will address that right away. On December 11, 2024, AnaptysBio announced topline results of its Phase 2B trial for ANB032 for the treatment of atopic dermatitis. The trial failed, and as a ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...